Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease

Part of paid clinical trials in Detroit, Michigan.

Sponsor
Henry Ford Health System
Study ID
NCT07646197
Status
Recruiting

Conditions

  • Fatty Liver
  • MASLD

Eligibility Criteria

Sex
ALL
Age
30 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Peanut consumption — OTHER
    MASLD patients will consume 50 gm of peanut daily for 12 weeks

Study Details

The aim of this randomized interventional trial is to understand the effects of peanut consumption on patients with metabolic associated fatty liver. The main goal is to investigate if patients who consume peanuts have improved liver marker tests as well as metabolic profile. We will also investigate how peanuts alter the gut microbes and liver fat content in patients with metabolic associated fatty liver. * Participants will be randomized into intervention (peanut consumption for 12 weeks) and control (regular diet) arm. * Stool sample and blood (for biomarkers) collection across both arms at baseline and post-intervention * Daily log to be completed for tracking peanut consumption * 2-day Dietary recall at baseline, during Week 6 and Week 12 * Poat intervention Fibro scans for participants with baseline scans available

Key Dates

Start date
Jun 9, 2026
Status verified
Jun 2026
Primary completion
Apr 6, 2028
Completion
Jun 9, 2028

Study Design

Enrollment
125 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Peanut
    MASLD patients will consume 50 gm of peanut daily for 12 weeks
  • No Intervention: Control
    Regular diet

Primary Outcome Measure

Hepatic Markers [ Time Frame: Baseline to post-intervention (12 weeks) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Henry Ford Health SystemDetroitMichigan48202
Menghua Tao, Ph.D.
3138768471

Find similar trials in Detroit, MI

Related Studies